Paper36689727
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.
Heidenreich F and 25 others. Blood Adv, 2023. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia. Papers, record 36689727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36689727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, KIR | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Case-Control Studies | |
| Ligands | |
| Genotype |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26983546 | The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. | J Hematol Oncol | 2016 | https://conductscience.org/library/papers/26983546 | PubMed |
| 2 | 31681270 | Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. | Front Immunol | 2019 | https://conductscience.org/library/papers/31681270 | PubMed |
| 3 | 18841361 | Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. | Cancer Immunol Immunother | 2009 | https://conductscience.org/library/papers/18841361 | PubMed |
| 4 | 30564239 | Allele-Level KIR Genotyping of More Than a Million Samples: Workflow, Algorithm, and Observations. | Front Immunol | 2018 | https://conductscience.org/library/papers/30564239 | PubMed |
| 5 | 32092137 | KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. | Blood Adv | 2020 | https://conductscience.org/library/papers/32092137 | PubMed |
| 6 | 12391228 | Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. | J Immunol | 2002 | https://conductscience.org/library/papers/12391228 | PubMed |
| 7 | 32102404 | Analysis of Killer Immunoglobulin-Like Receptor Genes in Colorectal Cancer. | Cells | 2020 | https://conductscience.org/library/papers/32102404 | PubMed |
| 8 | 26744525 | Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells. | Cancer Res | 2016 | https://conductscience.org/library/papers/26744525 | PubMed |
| 9 | 19903900 | Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. | Blood | 2010 | https://conductscience.org/library/papers/19903900 | PubMed |
| 10 | 24018270 | HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors. | J Immunol | 2013 | https://conductscience.org/library/papers/24018270 | PubMed |
| 11 | 31644966 | Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. | Leuk Res | 2019 | https://conductscience.org/library/papers/31644966 | PubMed |
| 12 | 33257819 | Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+ patients. | Genes Immun | 2020 | https://conductscience.org/library/papers/33257819 | PubMed |
| 13 | 29358179 | Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. | Blood | 2018 | https://conductscience.org/library/papers/29358179 | PubMed |
| 14 | 27446203 | The Impact of KIR Polymorphism on the Risk of Developing Cancer: Not as Strong as Imagined? | Front Genet | 2016 | https://conductscience.org/library/papers/27446203 | PubMed |
| 15 | 32767509 | Association of killer-cell immunoglobulin-like receptor genes with acute myelogenous leukaemia. | Int J Immunogenet | 2020 | https://conductscience.org/library/papers/32767509 | PubMed |
| 16 | 22768326 | Activating KIR and HLA Bw4 ligands are associated to decreased susceptibility to pemphigus foliaceus, an autoimmune blistering skin disease. | PLoS One | 2012 | https://conductscience.org/library/papers/22768326 | PubMed |
| 17 | 20600442 | Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. | Hum Immunol | 2010 | https://conductscience.org/library/papers/20600442 | PubMed |
| 18 | 31379844 | Natural Killer Cells Offer Differential Protection From Leukemia in Chinese Southern Han. | Front Immunol | 2019 | https://conductscience.org/library/papers/31379844 | PubMed |
| 19 | 19493232 | Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. | Tissue Antigens | 2009 | https://conductscience.org/library/papers/19493232 | PubMed |
| 20 | 25740999 | Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1. | J Virol | 2015 | https://conductscience.org/library/papers/25740999 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42712389 | Contrasting relapse rate associated with the absence of HLA-A3/A11 in T cell-replete haploidentical transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42712389 | PubMed |
| 40244151 | The Role of Killer Ig-like Receptors in Diseases from A to Z. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40244151 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36689727
GET https://conductscience.org/api/papers/v1/36689727/authors?page=2